查詢結果分析
相關文獻
- The Experience of Continuous Prone Position Ventilation in Patients with Severe Community--Acquired Pneumonia in Taichung Veterans General Hospital, Taiwan
- Acute Respiratory Distress Syndrome due to Chlamydia pneumoniae Infection in a Healthy Young Adult--A Case Report and Literature Review
- Modified Pneumonia Severity Index and Length of Hospital Stay in Patients with Community-Acquired Pneumonia: Experience of a Medical Center in Taiwan
- 探討Fluoroquinolones治療社區型肺炎
- Severe Community-Acquired Pneumonia Caused by Methicillin-Resistant Staphylococcus aureus
- Impact of Initial Antibiotic Choice on Clinical Outcomes of Community-Acquired Pneumonia in Adults
- Virulent Gram-Negative Bacilli Isolated in Sputum Culture Predict Length of Hospital Stay in Patients with Community-Acquired Pneumonia
- Outcome Analysis of Patients Requiring Mechanical Ventilation with Severe Community-Acquired Pneumonia and Identified Bacterial Pathogens
- 退伍軍人桿菌感染之社區型肺炎病例用藥探討
- 末期腎病變病患肺炎之預防--疫苗注射
頁籤選單縮合
| 題 名 | 探討Fluoroquinolones治療社區型肺炎=Fluoroquinolones in Treating Community-Acquired Pneumonia |
|---|---|
| 作 者 | 洪健雄; 鄭奕帝; 蕭淑珍; | 書刊名 | 藥學雜誌 |
| 卷 期 | 28:4=113 2012.12[民101.12] |
| 頁 次 | 頁62-67 |
| 分類號 | 418.281 |
| 關鍵詞 | 社區型肺炎; Community-acquired pneumonia; Respiratory fluoroquinolones; |
| 語 文 | 中文(Chinese) |
| 中文摘要 | 社區型肺炎 (community-acquired pneumonia)定義為肺實質之急性感染,發生於未住院或住院未滿 48小時的病人。其治療藥品之選擇,除了要視藥品的抗菌譜能否適當涵蓋社區型肺炎最為常見的病原菌外,其次要考慮藥品於社區病原菌的感受性。而下列三項 fluoroquinolones類抗生素 levofloxacin、moxifloxacin及 gemifloxacin因具有增強的抗肺炎鏈球菌活性,故又被稱之為 respiratory fluoroquinolones。本文之目的意在比較 fluoroquinolones於社區型肺炎治療的臨床結果,以探討其治療角色之崛起。 |
| 英文摘要 | Community-acquired pneumonia (CAP) is defined as an acute infection of lung parenchyma that develops in the outpatient setting or within 48 hours of admission to a hospital. The choice of empiric antibiotic regimen for the treatment of CAP is based on the likelihood that a given pathogen is present and on the antibiotic susceptibilities of pathogen in the community. Some fluoroquinolones have enhanced activity against Streptococcus pneumoniae (i.e. levofloxacin, moxifloxacin and gemifloxacin) referred respiratory fluoroquinolones. This review discusses the rise of the fluoroquinolone era, debates the comparative effectiveness of fluoroquinolone for CAP therapy. |
本系統中英文摘要資訊取自各篇刊載內容。